The Intel platform is an edge-to-cloud artificial intelligence platform that allows clinical data to be remotely monitored while it continuously captures data for study participants who are using wearable devices. The platform can then use machine learning techniques to measure symptoms and determine what the impact of therapies will be.
Icon experts and Intel’s AI and analytics experts collaborated on trials that are using the Intel Pharma Analytics Platform. The platform captures de-identified, objective, high-quality, rich sensory data through sensors and wearable devices and receives real-time information on protocol adherence while also helping patients manage medication. It also uses smartphone apps to gather electronic diaries and patient reported outcomes. The information that the platform gathers can be transmitted to a secure cloud infrastructure for storage and analysis while machine learning and other AI methods can assess and quantify the severity of symptoms and how different therapies are working.
“Intel is accelerating the pace of digital transformation, and IT plays a leading role in delivering solutions on that journey,” said Paula Tolliver, corporate VP and chief information officer at Intel. “With the power of AI, the Intel Pharma Analytics Platform helps the clinical trial industry reduce costs and deliver fresh insights for drug development, potentially saving thousands of lives.”
The Intel Pharma Analytics Platform is designed to help pharmaceutical companies who want to speed up and simplify clinical trials while reducing trial costs and gathering more objective evidence. It helps companies move to automatic collection of consistent, unbiased data, remote monitoring for data analysis and deliver improved patient experience.
“Our engagement with Intel confirms Icon’s position as the leading CRO for advancing the use of wearable technology, and will expand Icon’s existing offering to include a service where data can be aggregated and analyzed from mHealth and wearable technologies, with advanced analytics allowing for development of novel endpoints and digital biomarkers,” said Steve Cutler, CEO at Icon, in a press release. “Furthermore, the platform supports patient centric trial designs by reducing or eliminating the need for patients to travel to sites, and can be integrated with our Direct to Patient Call Center (DPC) providing a seamless compliance monitoring service.”